Indivior Chief Medical Officer Ponni Subbiah, M.D., Provides Testimony Before the US House of Representatives’ Energy and Commerce Subcommittee on Health Hearing on Combating the Opioid Crisis: Helping Communities Balance Enforcement and Patient Safety02.28.2018 | PDF Version
Richmond, VA, 28 February, 2018 – Today, Dr. Ponni Subbiah, Chief Medical Officer, Indivior, Inc. offered testimony on behalf of the Company before the US House of Representatives’ Energy and Commerce Subcommittee on Health Hearing on Combating the Opioid Crisis: Helping Communities Balance Enforcement and Patient Safety.
Please click here to read the written testimony submitted by Indivior to the Commission.
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is that all patients around the world have access to evidence-based treatment for the chronic condition and co-occurring disorders of addiction. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
+44 207 353 4200
Jason Thompson, Indivior
Vice President, Investor Relations